**Supplemental Material for COVID-19 in hospitalized patients on chronic peritoneal dialysis: A Case Series**

1. Northwell Nephrology Consortium Author list – **Page 2**
2. Supplemental Table 1: Details of peritoneal dialysis prescription for hospitalized patients with COVID-19, on chronic peritoneal dialysis- **Page 3**
3. Supplemental Table 2: Characteristics of peritoneal fluid and treatment course for patients with peritonitis- **Page 4**

**Northwell Nephrology COVID-19 Consortium authors**

Mersema Abate, MD, MPH; Hugo Paz Andrade, MD; Richard L. Barnett, MD; Alessandro Bellucci, MD; Madhu C. Bhaskaran, MD; Antonio G. Corona, MD; Bessy Suyin Flores Chang, MD; Mark Finger, MD; Steven Fishbane, MD; Michael Gitman, MD; Candice Halinski, MBA, MHCDS, MSN, NP-C; Shamir Hasan, MD; Azzour D. Hazzan, MD; Susana Hong, MD; Yuriy Khanin, MD; Aireen Kuan, MD; Varun Madireddy, MD; Deepa Malieckal, MD; Abdulrahman Muzib, MD; Gayatri Nair, MD; Jia Hwei Ng, MD, MSCE; Rushang Parikh, MD; Daniel W. Ross, MD, MPH; Vipulbhai Sakhiya, MBBS; Mala Sachdeva, MD; Richard Schwarz,MD; Hitesh H. Shah, MD; Purva Sharma, MD; Pravin C. Singhal, MD; Nupur N. Uppal, MD; Rimda Wanchoo, MD.

**Northwell COVID-19 Research Consortium authors**

Jamie S. Hirsch, MD,MA,MSB; Kenar D. Jhaveri, MD; Vinay V. Nair, DO

**Affiliations of the Northwell COVID-19 Research Consortium and Northwell Nephrology COVID-19 Consortium authors**

Division of Kidney Diseases and Hypertension, Donald and Barbara Zucker School of Medicine at Hofstra/Northwell, Northwell Health, Great Neck, NY 11021, USA.

**Supplemental Table 1: Details of peritoneal dialysis prescription for hospitalized patients with COVID-19, on chronic peritoneal dialysis**

|  |  |  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
| **Patient** | **1** | **2** | **3** | **4** | **5** | **6** | **7** | **8** | **9** | **10** | **11** |
| Type of PD | CAPD | CAPD | CAPD | CAPD | CAPD | CAPD | APD | APD | APD | APD | CAPD |
| Dialysate Solution | Alternate 1.5/2.5% dextrose | 1.5% dextrose, 2.5% dextrose for long dwell | 2.5% dextrose | 1.5% dextrose, 2.5% dextrose for long dwell | Alternate 4.25/2.5% dextrose, 4.25% dextrose for long dwell | 2.5% dextrose | 1.5% dextrose/ 7.5% icodextrin for last fill of 1.2L  | 2.5% dex-trose | Alternate1.5/2.5% dex-trose | Alternate 1.5% dextrose/ 2.5% dextrose | 2.5% dextrose |
| Number of ex-changes | 4 | 3 | 4 | 4 | 3-5 | 3 | 4-5 | 4 | 6 | 4 | 4 |
| Ex-change Volume (L) | 2 | 2 | 2 | 2 | 2.5 | 1.3 | 2 | 2 | 2.5 | 1.5-1.75 | 1.5-2 |
| Total treatment volume (L) | 8 | 6 | 8 | 8 | 7.5-12.5 | 3.9 | 9.2-11.2 | 8 | 15 | 6-7 | 6-8 |
| Total Treat-ment time (hours) | 24 | 24 | 24 | 24 | 24 | 24 | 8-9  | 6-8 | 12 | 10 | 24 |
| Average daily net UF (mL) | NA | -476 | NA | -590 | -920 | -550 | -500 | NA | NA | NA | -550 |

Abbreviations: CAPD, continuous ambulatory peritoneal dialysis; APD, Automated peritoneal dialysis; UF, Ultrafiltration; NA, Not available

|  |
| --- |
| **Supplemental Table 2: Characteristics of peritoneal fluid and treatment course for patients with peritonitis** |
|  | **Patient 2** | **Patient 4** | **Patient 8** |
| **Color** |  Colorless | Straw | Lavender |
| **Clarity** |  Hazy | Hazy | Yellow |
| **Total Nucleated Cells(cells/mm3)** |  743 | 274 | 640 |
| **Red blood cells(cells/mm3)** |  2 | <1000 | 21 |
| **Segmented Cells (%)** | 63 | 68 | 71 |
| **Lymphocytes (%)** | 22 | 3 | 9 |
| **Monocytes (%)** | 14 | 29 | 9 |
| **Culture** | Negative | Negative | Negative |
| **Peritonitis Treatment** | One dose ceftriaxone and azithromycin on admission and three subsequent doses of vancomycin dosed by level for two weeks. Not discharged home on further antibiotics. | One dose of ceftriaxone and azithromycin on admission; Not discharged home on further antibiotics | Piperacillin/tazobactam for seven days; Was not discharged home on further antibiotics. |